Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 trial evaluating the addition of ivosidenib to chemotherapy for IDH1-mutant relapsed or refractory acute myeloid leukemia, including…
-
CLINICAL_TRIALS research · 2025-01-08Clinical Trial Update: Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome
A clinical trial is evaluating the response to a biosimilar erythropoietin alfa therapy in anemic patients with myelodysplastic syndromes an…
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the combination of bortezomib and low-dose cytarabine in high-risk myelodysplastic syndromes has been co…
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia [Phase 1]
Phase 1 clinical trial update on the combination of ipilimumab and decitabine in patients with relapsed or refractory myelodysplastic syndro…
-
CLINICAL_TRIALS research · 2025-01-01Clinical Trial Update: Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis [Phase 2, Phase 3]
A multi-agent trial in pediatric and young adult patients explores preventing graft-versus-host disease after transplantation using post-tra…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-27Clinical Trial Update: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS [Phase 1]
Nkarta's NKX101 is an intravenous allogeneic CAR-NK cell therapy being studied in adults with relapsed/refractory acute myeloid leukemia and…
-
CLINICAL_TRIALS trial_result · 2024-12-20Clinical Trial Update: Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients [Phase 2]
Phase 2 trial evaluating posaconazole prophylaxis during ATG treatment in patients with aplastic anemia or myelodysplastic syndromes; the st…
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG [Phase 3]
Phase 3 randomized trial comparing post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prophylaxis…
-
FDA approval · 2024-12-19FDA Approved: AZACITIDINE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for azacitidine submitted by BluePoint Laboratories.
-
CLINICAL_TRIALS trial_result · 2024-12-19Clinical Trial Update: A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS [Phase 1, Phase 2]
A Phase Ib/II multicenter open-label study of bemcentinib (BGB324) in acute myeloid leukemia or myelodysplastic syndromes has completed and …
-
CLINICAL_TRIALS research · 2024-12-18Clinical Trial Update: COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome [NA]
A feasibility study on coaching and prehabilitation for patients with acute myeloid leukemia and myelodysplastic syndromes, sponsored by Ins…
-
CLINICAL_TRIALS trial_result · 2024-12-16Clinical Trial Update: Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents [Phase 2]
A Phase 2 trial update evaluating low-dose deferasirox in adults with low-risk myelodysplastic syndromes who are resistant or relapsing afte…
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [Phase 1]
Phase 1 clinical trial studying tagraxofusp in pediatric patients with CD123-expressing hematologic malignancies is currently recruiting, sp…
-
CLINICAL_TRIALS research · 2024-11-26Clinical Trial Update: Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification [Phase 2]
Phase II clinical trial evaluating a prophylactic intervention to prevent relapse after allogeneic transplantation in very high-risk myelody…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS [Phase 1]
Phase 1 trial update for PRGN-3006 adoptive cellular therapy targeting CD33-positive acute myeloid leukemia, including MRD-positive AML or h…
-
EMA approval · 2024-11-05EMA Authorised: Vidaza (azacitidine) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised Vidaza (azacitidine) in the EU for myelodysplastic syndromes and certain leukemias, including chronic myelomonocytic leuk…
-
CLINICAL_TRIALS research · 2024-10-30Clinical Trial Update: A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor [Phase 2]
Phase 2 multicenter trial evaluating azacitidine or ruxolitinib in combination with selinexor for MDS/MPN overlap syndrome; currently enroll…
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients [NA]
This clinical trial update describes a study on molecular mechanisms of relapse after allogeneic stem cell transplantation in myelodysplasti…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML [Phase 2]
Phase 2 clinical trial evaluating CD34-selected allogeneic hematopoietic stem cell transplantation with myeloablative conditioning plus CD8+…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion [Phase 2]
Phase 2 study in Japanese patients with IPSS-R very low/low or intermediate risk myelodysplastic syndromes not requiring red blood cell tran…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy [Phase 2]
Phase 2 trial investigating CPI-613 (devimistat) in patients with previously treated myelodysplastic syndromes. The study was terminated and…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
This clinical trial update describes a prospective evaluation of diagnosis and treatment among patients with autoimmune cytopenias, includin…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. [Phase 1]
Phase Ib clinical trial of APG-115 as a single agent or in combination with azacitidine or cytarabine for acute myeloid leukemia or myelodys…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies [Phase 2]
Phase 2 trial evaluating post-transplantation bendamustine and cyclophosphamide in refractory myeloid malignancies has completed.
-
FDA approval · 2024-10-15FDA Approved: AZACITIDINE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic azacitidine (AZACITIDINE) under an original application. The drug is indicated for myelodysplas…